miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer

Bo Chen; Hailin Tang; Xiaoping Liu; Peng Liu; Lu Yang; Xinhua Xie; Feng Ye; Cailu Song; Xiaoming Xie; Weidong Wei

doi:10.1016/j.canlet.2014.09.028

miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer

Cancer Lett. 2015 Jan 28;356(2 Pt B):410-7. doi: 10.1016/j.canlet.2014.09.028. Epub 2014 Oct 7.

Authors

Bo Chen¹, Hailin Tang¹, Xiaoping Liu¹, Peng Liu¹, Lu Yang¹, Xinhua Xie¹, Feng Ye¹, Cailu Song¹, Xiaoming Xie², Weidong Wei³

Affiliations

¹ Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.
² Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China. Electronic address: [email protected].
³ Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China. Electronic address: [email protected].

PMID: 25304371
DOI: 10.1016/j.canlet.2014.09.028

Abstract

It has been reported that miR-22 plays an important role and may be a promising therapeutic target in cancer. In this study, we found that GLUT1 is a direct target of miR-22. The ectopic expression of miR-22 inhibited breast cancer cell proliferation and invasion by targeting GLUT1. A reverse correlation between the expression of miR-22 and GLUT1 was observed in breast cancer tissue samples. Furthermore, miR-22 was significantly correlated with the TNM stage, local relapse, distant metastasis, and survival of breast cancer patients. Our data suggest that miR-22 functions as a tumor suppressor and is a promising prognostic biomarker in breast cancer.

Keywords: Breast cancer; GLUT1; Prognostic factor; miR-22.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Apoptosis
Blotting, Western
Breast Neoplasms / genetics*
Breast Neoplasms / metabolism
Breast Neoplasms / mortality
Breast Neoplasms / pathology
Cell Movement
Cell Proliferation
Female
Gene Expression Regulation, Neoplastic*
Glucose Transporter Type 1 / antagonists & inhibitors
Glucose Transporter Type 1 / genetics
Glucose Transporter Type 1 / metabolism*
Humans
Immunoenzyme Techniques
MicroRNAs / genetics*
Middle Aged
Neoplasm Invasiveness
Neoplasm Recurrence, Local / genetics*
Neoplasm Recurrence, Local / metabolism
Neoplasm Recurrence, Local / mortality
Neoplasm Recurrence, Local / pathology
Neoplasm Staging
Prognosis
RNA, Messenger / genetics
RNA, Small Interfering / genetics
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
Survival Rate
Tumor Cells, Cultured
Tumor Stem Cell Assay

Substances

Glucose Transporter Type 1
MIRN22 microRNA, human
MicroRNAs
RNA, Messenger
RNA, Small Interfering
SLC2A1 protein, human